Patents by Inventor John A Porco, Jr.
John A Porco, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11773086Abstract: The present invention is directed to compounds, compositions, and methods for inhibiting drug-efflux pumps. The compounds, compositions, and methods can be used for enhancing the activity of therapeutic agents that are efflux pump substrates and for the treatment of drug-resistant diseases or disorders, such as microbial infections and cancers.Type: GrantFiled: August 31, 2021Date of Patent: October 3, 2023Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Lauren E. Brown, Kaddy Camara, Leah E. Cowen, John A. Porco, Jr., Kali Rae Iyer
-
Patent number: 11427595Abstract: Described herein are compounds, agents, compositions, and methods related to the treatment of a viral infection (e.g., Hepatitis C viral infection). In particular, the compounds, agents, compositions, and methods described herein inhibit viral entry into a target cell.Type: GrantFiled: October 22, 2019Date of Patent: August 30, 2022Assignees: TRUSTEES OF BOSTON UNIVERSITY, SRI INTERNATIONALInventors: John A. Porco, Jr., Wenhan Zhang, Tony Tianyi Wang, Shufeng Liu
-
Patent number: 11279708Abstract: Herein are described the preparation of a series of synthetic rocaglates, amidino- and amino-rocaglates, which display inhibition of protein translation and tumor cell proliferation (in vitro and in vivo). The methods described herein allow the preparation of libraries of modified rocaglates. This chemical modification of the rocaglate scaffold changes the C8b-hydroxyl of the natural product series to a more optimal hydrogen bond donor/acceptor.Type: GrantFiled: June 11, 2020Date of Patent: March 22, 2022Assignee: TRUSTEES OF BOSTON UNIVERSITYInventors: John A. Porco, Jr., Wenhan Zhang, Gerard Pelletier, Jennifer Chu
-
Publication number: 20220064152Abstract: The present invention is directed to compounds, compositions, and methods for inhibiting drug-efflux pumps. The compounds, compositions, and methods can be used for enhancing the activity of therapeutic agents that are efflux pump substrates and for the treatment of drug-resistant diseases or disorders, such as microbial infections and cancers.Type: ApplicationFiled: August 31, 2021Publication date: March 3, 2022Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Lauren E. BROWN, Kaddy CAMARA, Leah E. COWEN, John A. PORCO, JR.
-
Publication number: 20210163387Abstract: Herein are described apparatus and processes for the preparation of cannabinoids, such as cannabidiol (CBD) and derivatives thereof. The apparatus and processes described can be used for the one-step, flow-mediated synthesis of cannabidiol and derivatives with improved overall yield, material throughput, and product purity relative to batch processes.Type: ApplicationFiled: January 14, 2021Publication date: June 3, 2021Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: John A. PORCO, JR., Aaron B. BEELER, Lauren E. BROWN, Richard V. TRILLES
-
Publication number: 20200392147Abstract: Herein are described the preparation of a series of synthetic rocaglates, amidino- and amino-rocaglates, which display inhibition of protein translation and tumor cell proliferation (in vitro and in vivo). The methods described herein allow the preparation of libraries of modified rocaglates. This chemical modification of the rocaglate scaffold changes the C8b-hydroxyl of the natural product series to a more optimal hydrogen bond donor/acceptor.Type: ApplicationFiled: June 11, 2020Publication date: December 17, 2020Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: John A. Porco, Jr., Wenhan Zhang, Jerry Pelletier, Jennifer Chu
-
Publication number: 20200123170Abstract: Described herein are compounds, agents, compositions, and methods related to the treatment of a viral infection (e.g., Hepatitis C viral infection). In particular, the compounds, agents, compositions, and methods described herein inhibit viral entry into a target cell.Type: ApplicationFiled: October 22, 2019Publication date: April 23, 2020Applicants: Trustees of Boston University, SRI InternationalInventors: John A. Porco, Jr., Wenhan Zhang, Tony Tianyi Wang, Shufeng Liu
-
Patent number: 10085988Abstract: A rocaglamide or a rocaglate derivative, particularly aglaroxin C, blocks hepatitis C virus (HCV) entry with improved potency and therapeutic index.Type: GrantFiled: September 19, 2016Date of Patent: October 2, 2018Assignees: SRI International, Trustees of Boston UniversityInventors: Tony Tianyi Wang, Shufeng Liu, Wenyu Wang, Neil Lajkiewicz, John A. Porco, Jr.
-
Patent number: 10087149Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that benefit from inhibition of HDAC8 activity.Type: GrantFiled: January 24, 2014Date of Patent: October 2, 2018Assignees: TRUSTEES OF BOSTON UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Aaron Beaty Beeler, John A. Porco, Jr., Oscar J. Ingham, James E. Bradner
-
Publication number: 20160102053Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.Type: ApplicationFiled: July 10, 2015Publication date: April 14, 2016Inventors: Gregory D. CUNY, Xin TENG, Junying YUAN, Alexei DEGTEREV, John A. PORCO, JR.
-
Publication number: 20150352079Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8).Type: ApplicationFiled: January 24, 2014Publication date: December 10, 2015Inventors: Aaron Beaty BEELER, John A. PORCO, JR., Oscar J. INGHAM, James E. BRADNER
-
Patent number: 9108955Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.Type: GrantFiled: January 10, 2014Date of Patent: August 18, 2015Assignees: President and Fellows of Harvard College, Tufts University, The Brigham and Women's Hospital, Inc., Trustees of Boston UniversityInventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterev, John A. Porco, Jr.
-
Patent number: 8658689Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.Type: GrantFiled: August 20, 2012Date of Patent: February 25, 2014Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc., Tufts University, Trustees of Boston UniversityInventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterev, John A. Porco, Jr.
-
Patent number: 8404088Abstract: The present invention provides a new strategies for the synthesis of compounds of the rocaglamide family and related natural products. The synthetic approach generally involves photochemical generation of an oxidopyrylium species from a 3-hydroxychromone derivative followed by an enantioselective 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile in the presence of a TADDOL derivative. This approach can be used for the formation of adducts containing an aglain core structure. Methods of the conversion of aglain core structures to aglain, rocaglamide and forbaglin ring systems are also provided. The present invention also relates to the use of rocaglamide/aglain/forbaglin derivatives for the manufacture of medicaments for use in the treatment of cancer or cancerous conditions, disorders associated with cellular hyperproliferation, or NF-?B-dependent conditions.Type: GrantFiled: March 19, 2012Date of Patent: March 26, 2013Assignee: Trustees of Boston UniversityInventors: John A. Porco, Jr., Baudouin Gerard
-
Publication number: 20120309795Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.Type: ApplicationFiled: August 20, 2012Publication date: December 6, 2012Inventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterev, John A. Porco, JR.
-
Publication number: 20120238766Abstract: The present invention provides a new strategies for the synthesis of compounds of the rocaglamide family and related natural products. The synthetic approach generally involves photochemical generation of an oxidopyrylium species from a 3-hydroxychromone derivative followed by an enantioselective 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile in the presence of a TADDOL derivative. This approach can be used for the formation of adducts containing an aglain core structure. Methods of the conversion of aglain core structures to aglain, rocaglamide and forbaglin ring systems are also provided. The present invention also relates to the use of rocaglamide/aglain/forbaglin derivatives for the manufacture of medicaments for use in the treatment of cancer or cancerous conditions, disorders associated with cellular hyperproliferation, or NF-?B-dependent conditions.Type: ApplicationFiled: March 19, 2012Publication date: September 20, 2012Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: John A. Porco, JR., Baudouin Gerard
-
Publication number: 20120094939Abstract: The present invention is directed to compounds of formulae (I) and (II) and pharmaceutically acceptable forms thereof; pharmaceutical compositions thereof; and methods of treating a viral infection, such as a hepatitis C virus (HCV) infection, by administering to a subject diagnosed with or being susceptible to the viral infection a compound of formulae (I) and (II), a pharmaceutically acceptable form thereof, or a pharmaceutical composition thereof. The present invention is also directed to high-throughput methods of identifying compounds able to modulate hepatitis C virus (HCV) replication activity.Type: ApplicationFiled: April 4, 2008Publication date: April 19, 2012Inventors: Stuart L. Schreiber, Raymond T. Chung, Lee F. Peng, Sun Suk Kim, Sirinya Matchacheep, John A. Porco, JR., Aaron B. Beeler
-
Patent number: 8137509Abstract: The present invention provides a new strategies for the synthesis of compounds of the rocaglamide family and related natural products. The synthetic approach generally involves photochemical generation of an oxidopyrylium species from a 3-hydroxychromone derivative followed by an enantioselective 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile in the presence of a TADDOL derivative. This approach can be used for the formation of adducts containing an aglain core structure. Methods of the conversion of aglain core structures to aglain, rocaglamide and forbaglin ring systems are also provided. The present invention also relates to the use of rocaglamide/aglain/forbaglin derivatives for the manufacture of medicaments for use in the treatment of cancer or cancerous conditions, disorders associated with cellular hyperproliferation, or NF-?B-dependent conditions.Type: GrantFiled: May 21, 2007Date of Patent: March 20, 2012Assignee: Trustees of Boston UniversityInventors: John A. Porco, Jr., Baudouin Gerard
-
Patent number: 8093288Abstract: Genipin derivatives and pharmaceutical compositions thereof that inhibit the activity of uncoupling protein-2 (UCP2) and are useful in treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemia in a mammal are disclosed.Type: GrantFiled: November 19, 2009Date of Patent: January 10, 2012Assignees: Beth Israel Deaconess Medical Center, Trustees of Boston UniversityInventors: Chen-Yu Zhang, Bradford B. Lowell, John A Porco, Jr., Ruichao Shen, Cheng T. Lin, Stefan Krauss
-
Publication number: 20110065786Abstract: The present invention provides new strategies for the synthesis of compounds of the rocaglamide family and related natural products. In particular, the new biomimetic synthetic approach involves photochemical generation of an oxidopyrylium species from a 3-hydroxychromone derivative followed by 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile. This approach can be used for the formation of adducts containing an aglain core structure. Methods for the conversion of aglain core structures to aglain, rocaglamide and forbaglin ring systems are also provided. The present invention also relates to the use of rocaglamide/aglain/forbaglin derivatives for the manufacture of medicaments for use in the treatment of cancer or cancerous conditions, disorders associated with cellular hyperproliferation, or NF-?B-dependent conditions.Type: ApplicationFiled: October 8, 2010Publication date: March 17, 2011Inventors: John A. Porco, JR., Baudouin Gerard, Guilford Jones, II